Sensei Biotherapeutics, Inc. (SNSE)
NASDAQ: SNSE · Real-Time Price · USD
9.09
0.00 (0.00%)
Feb 13, 2026, 4:00 PM EST - Market closed
Sensei Biotherapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
15
Market Cap
11.47M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2010 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2008 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2007 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| BioAtla | 11.00M |
| Longeveron | 1.44M |
| CytoMed Therapeutics | 573.19K |
| BioCardia | 3.00K |
| Soligenix | 2.34K |
SNSE News
- 5 weeks ago - Egle Therapeutics Appoints John Celebi as Chief Executive Officer - GlobeNewsWire
- 3 months ago - Sensei Biotherapeutics Reports Third Quarter 2025 Financial Results - GlobeNewsWire
- 3 months ago - Sensei Biotherapeutics Announces Initiation of Strategic Review to Maximize Shareholder Value - GlobeNewsWire
- 4 months ago - Sensei Biotherapeutics Reports New Clinical Results Highlighting Durable Progression Free Survival Data for Solnerstotug in PD-(L)1 Resistant Tumors at the ESMO Congress 2025 - GlobeNewsWire
- 5 months ago - Sensei Biotherapeutics to Host Virtual KOL Event to Discuss Full Dose Expansion Data for Solnerstotug in PD-(L)1 Resistant Tumors on October 20, 2025 - GlobeNewsWire
- 5 months ago - Sensei Biotherapeutics to Participate in the H.C. Wainwright 27th Annual Global Investment Conference - GlobeNewsWire
- 6 months ago - Sensei Biotherapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 7 months ago - Sensei Biotherapeutics to Present Clinical Data from the Phase 1 Dose Expansion Cohort of Solnerstotug at the ESMO Congress 2025 - GlobeNewsWire